JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

JNJ

234.31

+0.56%↑

UNH

275.55

-2.98%↓

TMO

563.68

-0.84%↓

ABT

108.15

-0.74%↓

ISRG

478.08

-0.13%↓

Search

Stryker Corp

Uždarymo kaina

SektoriusSveikatos priežiūra

360.47 0.16

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

356.48

Max

368.57

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-10M

849M

Pardavimai

1.1B

7.2B

P/E

Sektoriaus vid.

43.878

84.243

Pelnas, tenkantis vienai akcijai

4.47

Dividendų pajamingumas

0.92

Pelno marža

11.839

Darbuotojai

53,000

EBITDA

351M

1.7B

Rekomendacijos

By TipRanks

Rekomendacijos

Stiprus pirkimas

12 mėnesių prognozė

+17.4% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

0.92%

2.28%

Kitas uždarbis

2026-04-30

Kitas dividendų mokėjimo data

2026-04-29

Kita Ex Dividend data

2026-03-30

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

4.3B

141B

Ankstesnė atidarymo kaina

360.31

Ankstesnė uždarymo kaina

360.47

Naujienos nuotaikos

By Acuity

23%

77%

54 / 352 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

Stryker Corp Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-01-29 22:05; UTC

Uždarbis

Stryker Logs Higher 4Q Profit On Sales Gains

2025-10-30 20:36; UTC

Uždarbis

Stryker Lifts Fiscal Year Sales View After 3Q Revenue Rises

2025-07-31 20:42; UTC

Uždarbis

Stryker Lifts Guidance on Improving Tariff Outlook

2025-05-01 20:56; UTC

Uždarbis

Stryker Lowers Adjusted EPS View on $200 Million Tariff Impact

2026-01-30 17:03; UTC

Rinkos pokalbiai

Stryker's 4Q Results Signal 2026 Growth -- Market Talk

2026-01-29 21:07; UTC

Uždarbis

Stryker Sees 2026 Organic Net Sales Growth 8%-9.5%

2026-01-29 21:05; UTC

Uždarbis

Stryker 4Q Adj EPS $4.47 >SYK

2025-11-05 19:38; UTC

Uždarbis

This Healthcare Stock Is the Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

2025-11-05 17:00; UTC

Uždarbis

This Healthcare Stock Is Worst Performer in the S&P 500 Today. Here's Why. -- Barrons.com

2025-10-30 20:21; UTC

Uždarbis

Stryker Lifts FY Sales View After 3Q Revenue Rises

2025-10-30 20:05; UTC

Uždarbis

Stryker 3Q Adj EPS $3.19 >SYK

2025-10-30 20:05; UTC

Uždarbis

Stryker 3Q EPS $2.22 >SYK

2025-10-30 20:05; UTC

Uždarbis

Stryker 3Q Sales $6.1B >SYK

2025-10-30 20:05; UTC

Uždarbis

Stryker 3Q Net $859M >SYK

2025-10-30 20:05; UTC

Uždarbis

Stryker Sees FY Adj EPS $13.50-Adj EPS $13.60 >SYK

2025-10-30 20:05; UTC

Uždarbis

Stryker 3Q Adj EPS $3.19 >SYK

2025-10-30 20:05; UTC

Uždarbis

Stryker 3Q Net $859M >SYK

2025-10-30 20:05; UTC

Uždarbis

Stryker 3Q Sales $6.06B >SYK

2025-10-30 20:05; UTC

Uždarbis

Stryker 3Q EPS $2.22 >SYK

2025-07-31 20:09; UTC

Uždarbis

Stryker Estimates Net Impact From Tariffs in 2025 of Approximately $175M

2025-07-31 20:09; UTC

Uždarbis

Stryker Sales >SYK

2025-07-31 20:09; UTC

Uždarbis

Stryker Sees FY25 Organic Net Sales Up 9.5%-10%

2025-07-31 20:05; UTC

Uždarbis

Stryker 2Q Sales $6B >SYK

2025-07-31 20:05; UTC

Uždarbis

Stryker 2Q Net $884M >SYK

2025-07-31 20:05; UTC

Uždarbis

Stryker Sees FY Adj EPS $13.40-Adj EPS $13.60 >SYK

2025-07-31 20:05; UTC

Uždarbis

Stryker 2Q EPS $2.29 >SYK

2025-07-31 20:05; UTC

Uždarbis

Stryker 2Q Adj EPS $3.13 >SYK

2025-07-31 20:05; UTC

Uždarbis

Stryker 2Q Sales $6B >SYK

2025-07-31 20:05; UTC

Uždarbis

Stryker 2Q EPS $2.29 >SYK

2025-07-31 20:05; UTC

Uždarbis

Stryker 2Q EPS $2.29 >SYK

Akcijų palyginimas

Kainos pokytis

Stryker Corp Prognozė

Kainos tikslas

By TipRanks

17.4% į viršų

12 mėnesių prognozė

Vidutinis 432.21 USD  17.4%

Aukščiausias 469 USD

Žemiausias 387 USD

Remiantis 21 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Stryker Corp kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

21 ratings

18

Pirkti

3

Laikyti

0

Parduoti

Techninis įvertinimas

By Trading Central

373.92 / 383.99Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Rinkos nuotaikos

By Acuity

54 / 352 reitingas Sveikatos priežiūra

Naujienos nuotaikos

Labai stiprus bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Žemiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę Stryker Corp

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that include fixation, minimally invasive and interbody systems used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, clinical communication and workflow solutions, and other medical device products that are used in various medical specialties, as well as patient and caregiver safety technologies. This segment also provides neurosurgical, neurovascular and craniomaxillofacial implant products, which include products used for minimally invasive endovascular procedures; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Portage, Michigan.
help-icon Live chat